Cross Country Healthcare Inc (CCRN, Financial) is set to release its Q3 2024 earnings on Nov 6, 2024. The consensus estimate for Q3 2024 revenue is $310.22 million, and the earnings are expected to come in at $0.10 per share. The full year 2024's revenue is expected to be $1.35 billion and the earnings are expected to be $-0.18 per share. More detailed estimate data can be found on the Forecast page.
Cross Country Healthcare Inc (CCRN, Financial) Estimates Trends
Revenue estimates for Cross Country Healthcare Inc (CCRN) have declined from $1.35 billion to $1.35 billion for the full year 2024 and from $1.32 billion to $1.30 billion for 2025 over the past 90 days. Earnings estimates for Cross Country Healthcare Inc (CCRN) have declined from $-0.06 per share to $-0.18 per share for the full year 2024 and from $0.72 per share to $0.67 per share for 2025 over the past 90 days.
Cross Country Healthcare Inc (CCRN, Financial) Reported History
In the previous quarter of June 30, 2024, Cross Country Healthcare Inc's (CCRN) actual revenue was $339.77 million, which beat analysts' revenue expectations of $334.76 million by 1.5%. Cross Country Healthcare Inc's (CCRN) actual earnings were $-0.47 per share, which missed analysts' earnings expectations of $0.11 per share by -527.27%. After releasing the results, Cross Country Healthcare Inc (CCRN) was down by -3.78% in one day.
Cross Country Healthcare Inc (CCRN, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 5 analysts, the average target price for Cross Country Healthcare Inc (CCRN) is $18.20 with a high estimate of $19 and a low estimate of $15. The average target implies an upside of 62.36% from the current price of $11.21.
Based on GuruFocus estimates, the estimated GF Value for Cross Country Healthcare Inc (CCRN, Financial) in one year is $14.08, suggesting an upside of 25.60% from the current price of $11.21.
Based on the consensus recommendation from 8 brokerage firms, Cross Country Healthcare Inc's (CCRN, Financial) average brokerage recommendation is currently 2.4, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
